Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function.

Singh N, Hofmann TJ, Gershenson Z, Levine BL, Grupp SA, Teachey DT, Barrett DM.

Cytotherapy. 2017 Jul;19(7):867-880. doi: 10.1016/j.jcyt.2017.04.001. Epub 2017 May 11.

PMID:
28506444
2.
3.

Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer - Authors' response.

Brose MS, Singh N.

Lancet Oncol. 2016 Nov;17(11):e469. doi: 10.1016/S1470-2045(16)30520-4. No abstract available.

PMID:
27819236
4.

CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.

Singh N, Frey NV, Grupp SA, Maude SL.

Curr Treat Options Oncol. 2016 Jun;17(6):28. doi: 10.1007/s11864-016-0406-4. Review.

PMID:
27098534
5.

T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma.

Singh N, Kulikovskaya I, Barrett DM, Binder-Scholl G, Jakobsen B, Martinez D, Pawel B, June CH, Kalos MD, Grupp SA.

Oncoimmunology. 2015 Aug 12;5(1):e1040216. eCollection 2016.

6.

Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies.

Singh N, Perazzelli J, Grupp SA, Barrett DM.

Sci Transl Med. 2016 Jan 6;8(320):320ra3. doi: 10.1126/scitranslmed.aad5222.

PMID:
26738796
7.

Donor-derived CD19 chimeric antigen receptor T cells.

Singh N, Barrett DM.

Curr Opin Hematol. 2015 Nov;22(6):503-8. doi: 10.1097/MOH.0000000000000179. Review.

PMID:
26457962
8.

Roadblocks to success for RNA CARs in solid tumors.

Singh N, Barrett DM, Grupp SA.

Oncoimmunology. 2015 Jan 7;3(12):e962974. eCollection 2014 Dec.

9.

Combined B12 and folate deficiency presenting as an aggressive hematologic malignancy.

Singh N, Qayyum S, Wasik MA, Luger SM.

Am J Hematol. 2015 Oct;90(10):964-5. doi: 10.1002/ajh.23987. Epub 2015 Apr 29. No abstract available.

10.

Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.

Singh N, Liu X, Hulitt J, Jiang S, June CH, Grupp SA, Barrett DM, Zhao Y.

Cancer Immunol Res. 2014 Nov;2(11):1059-70. doi: 10.1158/2326-6066.CIR-14-0051. Epub 2014 Aug 7.

11.

Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy.

Barrett DM, Singh N, Liu X, Jiang S, June CH, Grupp SA, Zhao Y.

Cytotherapy. 2014 May;16(5):619-30. doi: 10.1016/j.jcyt.2013.10.013. Epub 2014 Jan 16.

12.

Chimeric antigen receptor therapy for cancer.

Barrett DM, Singh N, Porter DL, Grupp SA, June CH.

Annu Rev Med. 2014;65:333-47. doi: 10.1146/annurev-med-060512-150254. Epub 2013 Nov 20. Review.

13.

Immunotherapy for ovarian cancer: what's next?

Kandalaft LE, Powell DJ Jr, Singh N, Coukos G.

J Clin Oncol. 2011 Mar 1;29(7):925-33. doi: 10.1200/JCO.2009.27.2369. Epub 2010 Nov 15. Review.

14.

The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

Kandalaft LE, Singh N, Liao JB, Facciabene A, Berek JS, Powell DJ Jr, Coukos G.

Gynecol Oncol. 2010 Feb;116(2):222-33. doi: 10.1016/j.ygyno.2009.11.001. Epub 2009 Dec 2. Review.

Supplemental Content

Loading ...
Support Center